Emerging Therapeutic Targets: Rheumatoid Arthritis
Abstract
Rheumatoid arthritis involves a range of various intricate pathophysiologic facets that contribute to synovitis, synovial hyperplasia, autoantibodies generation as well as cartilage and bone damage leading to functional impairment. Although current therapeutic modalities including NSAIDs, corticosteroids, DMARDs and biologic response modifiers target various contributory factors but still not effectual in the apt management of rheumatoid arthritis, thus pointing towards the investigation of new prospects to not only manage but cure this perplexing disorder. Hence, Tumor necrosis factor-α converting enzyme (TACE/ADAM17), Toll like receptor 5 (TLR5), Citrullinated immunoglobulin binding protein (citBiP), anti-BRAF autoantibodies, Perforin and membrane attack complex (MAC), Migration inhibitory factor of macrophages (MIF), Mucin (MUCs), IL-1β, NLRP3 inflammasome signaling, NETosis, Hepatocyte growth factor (HGF), progranulin, PTPN22, iRHOM2, immune mediated immunolytic pathways, tenascin-C and various chemokines are intriguing areas, which in future might be more beneficial in the treatment and management of arthritis in majority of populace with minimum risks.
Submitting a manuscript to a journal implies that the work has not previously been published in any other journal, printed or online (save as an abstract or an academic thesis), and that it is not currently being considered for publication elsewhere.
